Kodiak Sciences Inc. (KOD)

3.8700 -0.5400 (-12.24%) At close: 04:00PM EDT

Kodiak Sciences Inc.

1200 Page Mill Road
Palo Alto, CA 94304
United States
650 281 0850
https://kodiak.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 111

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Victor Perlroth M.D.	Co-Founder, Chairman, CEO & President	1.08M	N/A	1973
Mr. John A. Borgeson CPA, M.B.A.	Senior VP, CFO & Secretary	667.52k	N/A	1962
Dr. Michael S. Louie Ph.D.	Senior VP of Digital Transformation & Chief Information Officer	N/A	N/A	N/A
Dr. Hong Liang	Senior Vice President of Discovery Medicine	300.71k	N/A	1972
Dr. Stephen Raillard Ph.D.	Senior Vice President of Chemical Development & Manufacturing	N/A	N/A	N/A
Ms. Almas Qudrat M.Sc.	Senior Vice President of Quality Operations	N/A	N/A	N/A
Dr. J. Pablo Velazquez-Martin M.D.	Senior VP of Clinical Research & Development	N/A	N/A	N/A
Tracy Chien	VP & Corporate Controller	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF; and KSI-101 (KSI-501P), an unconjugated bispecific protein targeting IL-6 and VEGF developed for retinal inflammatory conditions. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Corporate governance

Kodiak Sciences Inc.’s ISS governance QualityScore as of 1 April 2024 is 9. The pillar scores are Audit: 3; Board: 9; Shareholder rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.